Fat Loss & Metabolic
$70
10 vials · 5 mg. Price is for 10 vials.
Dual GIP and GLP-1 receptor agonist approved in the United States for specific diabetes and weight-related indications, depending on product labeling.
Strength
Quantity
Sold in packs of 10 vials. Tirzepatide 5 mg is priced per pack, not per milligram.
Need help? Contact on Telegram.
Research-use vials sold in packs of 10. Not a medicine and not for human or veterinary use. This catalog is not medical advice. Checkout is Telegram; see terms and privacy.
Intended use: research-use lyophilized peptide. This listing is not a medicine and not for human or veterinary use.
Form: powder in multi-dose vials. Pack of 10 vials at 5 mg.
Storage: keep lyophilized vials cool, dry, and away from sunlight. This page does not provide mixing steps or injection technique.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Mounjaro and Zepbound are example U.S. products with different labeled uses. Prescribing information is the source of record for indications, warnings, and administration.
Educational answers from the research profile. Not treatment advice.
A dual GIP and GLP-1 receptor agonist sold as FDA-approved products such as Mounjaro and Zepbound.
Product-specific uses include type 2 diabetes glycemic control (Mounjaro) and indicated weight-related uses (Zepbound). Confirm the current label.
It activates GIP and GLP-1 receptors involved in incretin and energy-balance signaling.
Yes, as specific prescription products beginning with U.S. approval in 2022.
Boxed thyroid C-cell warning, gastrointestinal effects, and other PI warnings. This page is not a complete safety list.